QMoat Research
Quality-investing analysis, company research and long-term investment insights in Healthcare.
Lilly’s volumes and gross margins rose despite lower prices. One-off revenue benefits, acquisition charges and a 36.3x guidance multiple complicate the investment case.
Stronger organic growth and margins support Thermo Fisher’s recovery. At roughly 27.5 times guided adjusted earnings, however, investors also need better returns on the capital committed to acquisitions.
Align Technology ended the year with a rare combination: record Invisalign shipments, improving profitability, and a steadier tone from management. The catch is familiar—average revenue per case is still drifting down as growth tilts toward lower-priced markets and heavier discounts, forcing the company to prove it can expand margins through productivity, not pricing power.
Zoetis shares plunged after a rare growth wobble in its pet-health franchise. But with margins intact and valuations reset, the selloff looks more like the end of a perfection trade than a structural break—raising the question: is this the moment to buy?
If giredestrant can secure a broad label and embed itself in treatment guidelines as a preferred endocrine partner, it would reinforce Roche’s franchise in breast cancer and create a recurring revenue stream with unusually high duration
Behind the quiet hum of hospital labs lies one of healthcare’s toughest moats. Roche, Abbott, and Danaher have built diagnostics empires so entrenched that rivals can’t pry them loose—analyzers, reagents, and data all locking customers in for decades.
Positive evERA data make giredestrant a real contender in HR+/HER2– breast cancer. Late-line use points to ~$1B peak; earlier-line wins could multiply that.
Novo’s Wegovy pill matches injection in weight loss, widening access as rivals like Lilly push oral GLP-1s in a fast-heating obesity race.
Artificial intelligence is moving from hype to lab bench, reshaping drug discovery, trial design, and pharma’s regulatory playbook.
Galderma rides the GLP-1 “face” wave, bets on Relfydess launch and China expansion to take share from AbbVie in aesthetics.
The Danish drugmaker built the modern market for obesity treatments—then let rival Eli Lilly steal the next big step.
President Donald Trump has reopened the political and commercial shooting war between pharmacy‑benefit managers and the drug makers they help police, signing a string of executive orders designed to prise open one of America’s most opaque supply chains and deliver cheaper medicines to voters wear…
Investors who can stomach a few quarters of volatility should treat Novo’s recent stumbles as the sort of discount that doesn’t linger long in obesity’s gold rush.